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Background: c-Met, one of current potential hot targets, has been suggested as a potential tumor marker in the
development of esophageal squamous cell carcinoma (ESCC). Our aim was to investigate the expression of c-Met in
advanced esophageal squamous cell carcinoma in four phase II trials who had tumor tissues from archival in our
center and analyze the correlations between c-Met expression and clinical features.
Methods: Ninety patients with advanced ESCC who were admitted to the phase II clinical trials in the Department
of Gastrointestinal Oncology, Peking University Cancer Hospital and Institute from March 2007 to March 2014 were
finally eligible for present study and the corresponding tissues and clinical data were collected. The expression of
c-Met in the tissue samples was detected by immunohistochemistry (IHC). c-Met overexpression was defined
as ≥ the median value of H-score. Kaplan-Meier and Cox multivariate regression were conducted to evaluate the
relationship between c-Met expression and ESCC survival.
Results: The overexpression of c-Met is 43.3% in advanced ESCC. There was no statistical difference between c-Met
expression and clinical features except sex and tumor location. Survival analysis documented that the overexpression of
c-Met predicted a worse prognosis (OS: 253 d vs 422 d, P = 0.011). In the group treated with chemotherapy combined
with anti-EGFR drugs, patients with lowexpression of c-Met had a better OS than those with overexpression of c-Met
(OS: 577 d vs 232 d, P = 0.007).
Conclusions: c-Met may be an independent prognostic factor in advanced ESCC. The overexpression of c-Met may
predict a worse efficacy of anti-EGFR therapy.
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Esophageal carcinoma is one of the most common
gastrointestinal cancers, the incidence of which ranks
the fifth among all of the malignant cancers in China
[1]. More than 95% of esophageal cancer in China is
esophageal squamous cell carcinoma (ESCC). Due to the
atypical clinical symptoms, most patients develop into
advanced stages when first diagnosed and lost operation
opportunity. Systematic therapies, including chemother-
apy, are of great importance for patients with advanced
ESCC, whereas the efficacy of chemotherapy based on 5-
FU/DDP/PTX is limited. As the ubiquity poor prognosis* Correspondence: lin100@medmail.com.cn
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unless otherwise stated.of advanced ESCC, new strategies are urgently needed, es-
pecially of targeted-therapy. c-Met is one of the most im-
portant factors with cancer-associated receptors and
pathways. c-Met tyrosine kinase is the cell-surface recep-
tor for hepatocyte growth factor (HGF) which is involved
in regulating cell proliferation, apoptosis, and migration.
c-Met activity is normally detected in defined stages of
embryogenesis and organogenesis [2-7]. HGF and c-Met
have a significant relevance to lymph node stage and dis-
tant metastasis. It was reported that c-Met was involved in
a number of human primary tumors, including gastric,
breast, colorectal, liver and renal cancer [8].
Recently, a meta-analysis focusing on c-Met overex-
pression and the prognosis of gastric cancer including
14 studies [9] indicated that higher amplification and ex-
pression of c-Met gene in gastric cancer is an indicator
of poor prognosis. c-Met was overexpressed in 34%-54%is an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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association with survive [10]. c-Met overexpression in
ESCC is about 7% and not correlated with prognosis in
western countries. Our study in China showed that c-Met
overexpression in ESCC is about 34% [11], which differs
from western countries. However, by now, there is no
study on the c-Met expression and clinical significance in
advanced ESCC.
Therefore, in this study, we detected c-Met expression
in advanced ESCC patients who involved in the phase II
clinical trials in our center. We investigated the expres-
sion levels of c-Met in advanced ESCC and estimated
the relationship between c-Met expression and clinical
features.
Methods
Patients and tumor specimens
Tumor samples were retrospectively identified from pa-
tients with ESCC who were enrolled in four phase II
clinical trials between 2007 and 2014 at the Peking Uni-
versity Cancer Hospital in Beijing, China. Four phase II
clinical trials for first-line treatment of ESCC were in-
volved: Paclitaxel and Cisplatin in Patients With Ad-
vanced Squamous-Cell Carcinoma of the Esophagus
[12]; Irinotecan Combined With Cisplatin as 1st Line
Treatment for Esophageal Squamous Cell Cancer: a Sin-
gle Center Prospective Clinical Trial (NCT01051765);
Study of Nimotuzumab to Treat Esophageal Squamous
Cell Carcinoma (NCT01993784); Sequential Paclitaxel
Chemotherapy and Radiotherapy as 1st Line Treatment for
Elderly Esophageal Squamous Cell Cancer (NCT02016287).
The inclusion and exclusion criteria were as follows:
Inclusion criterion:
1. Histological confirmed stage IV according to AJCC
6.0 or recurrent ESCC.
2. Patients have not received any palliative
chemotherapy or radiotherapy before.
3. Adjuvant therapies should be received more than
6 months before recurrence.
Exclusion criterion:
1. Adjuvant therapies are received within 6 months
before recurrence.
2. Patients who have other primary carcinomas except
ESCC.
3. Histology confirmed mixed tumor.
Anti-total c-Met (SP44) rabbit monoclonal primary anti-
bodies were purchased from Ventana Company (Ventana
Medical System, Tucson, USA).
Tissue samples for diagnostic purposes were obtained
with the consent of each patient. All tumor specimenswere fixed in 10% buffered formalin, embedded in paraf-
fin and then made into continuous 4 μm tissue sections
for IHC examination.
All patients signed written informed consent for their
information to be used for study. Study approval was ob-
tained from independent ethics committees at Peking
University Cancer Hospital. The study was undertaken
in accordance with the ethical standards of the World
Medical Association Declaration of Helsinki.
Immunohistochemistry (IHC)
IHC evaluation was performed using anti-total c-Met
(SP44) rabbit monoclonal primary antibody. The staining
was carried out according to the manufactures’ protocol
on the BenchMark XT platform from Ventana utilizing
the ultraView detection kit. The c-Met staining intensities
were evaluated by two pathologists who were blinded to
the diagnosis of individual patients. c-Met was localized
primarily in the cytoplasm and membrane. Specifically, in-
tensity was scored according to a four-tier systems: 0, no
staining; 1+, weak; 2+, moderate; and 3+, strong.
To our knowledge, there were no validated scoring sys-
tems for interpretation of c-Met staining intensity. Here,
positive results were judged by two systems of criterion.
1. H-score assessment was based on staining intensity
(0–3) and the percentage of positive cells (0-100%).
Each individual intensity level was multiplied by the
percentage of cells and all values were added to obtain
the final IHC score, ranging from 0 to 300. The final
score was calculated from the scores of assessment at
membranous and cytoplasmic expression.
2. The other evaluation of c-Met was performed
according to MetMab IHC defined scoring criteria
(positively defined as having ≥ 50% of tumor cells
positive for membranous or cytoplasmic and/or
c-Met immunostaining with moderate or strong
intensity, i.e. ≥ 2+) in the clinical trial of NCT01456325,
a MetMab phase III trial in advanced NSCLC [13].
Statistical analysis
A number of prognostic factors between different c-Met
expression groups were examined in univariate analysis.
These factors included: (1) sex: male and female; (2)
baseline age, dichotomized as ≤59 years vs. >59 years;
(3) tumor location; (4) presence of distant metastasis;
and (5) presence of lymph node invasion. Comparison of
categorical variables was performed with the chi-square
test or the Fisher’s exact test. Initial analysis involved a
univariate investigation of relationship between c-Met
overexpression and OS time using Kaplan-Meier survival
curves. To identify independent biomarkers, multivariate
analyses adjusted for the baseline variables were per-
formed using a Cox regression model for OS. P values
Figure 1 The patients screening process.
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performed using SPSS 19.0 software (IBM, Armonk, NY).
Results
Patients’ characteristics and c-Met expression
After screening all the patients’ medical record, one
hundred and ten cases were detected for c-Met IHC
(Figure 1). Due to limited tumor tissues, ninety casesFigure 2 The representative c-Met staining intensities were localized
1+, weak; 2+, moderate; and 3+, strong.were successfully detected. The representative IHC in-
tensity of c-Met expression is described in Figure 2. All
patients were followed up till Nov 6, 2014. Of the 90 pa-
tients, 63 died, 19 survived, and 8 were lost.
H-score of c-Met IHC ranged from 0 to 270, with the
median value of 20, which was chosen as the cutoff
point for separating c-Met over-expression tumors from
c-Met low-expression tumor. Of the 90 patients, 51 cases
had an H-score ≤ 20, considered as IHC low-expression,
and 39 cases had an H-score > 20, considered as IHC
over-expression. No statistically significant difference of
c-Met expression was found between different groups of
sex, age, tumor location, tumor differentiation, lymph
node invasion and distant metastasis (Table 1).
c-Met expression correlated with patient survival in
advanced ESCC
The relationship between OS and clinical features of
ESCC patients was analyzed through log-rank and chi-
square test. The results showed that no statistical signifi-
cance of OS was found in different groups of age, stage,
distant metastasis, tumor differentiation. However, OS
was significantly different by sex and tumor location.
Female patients had a better prognosis than male pa-
tients (577d vs 333d, P = 0.041). Patients with tumor lo-
cated in upper thoracic (475d) and middle thoracic
(422d) had a better prognosis than those in lower thor-
acic (258d) (P = 0.005).
Progress-free survival(PFS) was not significantly differ-
ent between the two c-Met expression groups (the median
PFS of c-Met over-expression vs c-Met low-expression:primarily in the cytoplasm and membrane. Intensity: 0, no staining;
Table 1 The relationship between c-Met expression and
clinical features of ESCC (according to H-score)
N H-score≤ 20 H-score > 20 P
Sex
Male 73 39 34 0.198
Female 17 12 5
Age
≤59 45 25 20 0.832
>59 45 26 19
Tumor location
Upper thoracic 6 4 2 0.489
Middle thoracic 48 24 24
Lower thoracic 35 22 13
Abdominal 1 1 0
Tumor differentiation
Poor 31 16 15 0.769
Moderate 46 27 19
Well 13 8 5
Distant metastasis
Yes 27 13 14 0.286
Liver 14 8 6 0.969
Lung 19 8 11 0.114
No 64 38 25
Lymph node invasion
Yes 85 48 37 0.877
No 5 3 2
Figure 3 Kaplan-Meier survival curves of patients with ESCC accordin
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CI 252d-482d). The OS was closely related to the expres-
sion of c-Met in ESCC tissues. As shown in Figure 3, the
survival rate of c-Met over-expression patients was signifi-
cantly lower than that in the low-expression group (253d
vs 422d, P = 0.011). In the multivariate Cox regression
model adjusted for baseline variants, there was still a stat-
istical significance between OS and c-Met expression
(HR = 1.805, 95% CI = 1.045-3.117, P = 0.034).
In this study, 25 patients received chemotherapy of
taxol and cisplatin (TP) plus nimotuzumab, 55 patients
received chemotherapy of TP alone, and 10 patients re-
ceived other chemotherapies. In c-Met overexpression
group, OS of patients who received TP plus nimotuzu-
mab was not different from that of patients who received
TP alone (232d vs 258d, P = 0.221). Similar results were
obtained in c-Met low-expression group (577d vs 422d,
P = 0.152). In TP plus nimotuzumab group, the OS of
patients with c-Met low-expression was significantly bet-
ter than those with c-Met over-expression (577d vs
232d, P = 0.007). In TP alone group, no statistical signifi-
cance was found (422d vs 258d, P = 0.076) (Figure 4).
The other evaluation of c-Met was performed accord-
ing to MetMab IHC defined scoring criterion. According
to this criterion, 16 patients (17.8%) had c-Met over-
expression and 74 patients (82.2%) had c-Met low-
expression. There was no significant relevance between
c-Met expression and different groups of age, sex, tumor
location, tumor differentiation, distant metastasis. The
patients with c-Met low-expression had a trend of better
prognosis with no statistical significance (P = 0.289).g to c-Met expression.
Figure 4 Kaplan-Meier survival curves of patients with ESCC according to treatment and c-Met expression.
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c-Met expression has been reported in a number of hu-
man primary tumors, including gastric, breast, colorec-
tal, liver and renal cancer. c-Met plays an important role
in tumor development and metastasis [8]. As the only
receptor of HGF, c-Met kinase activation resulting in ac-
tivation of downstream signaling which intermediates
such as mitogen-activated protein kinase (MAPK), mam-
malian target of rapamycin (mTOR) pathway, and signal
transducer and activator of transcription (STAT) path-
way which leads to changes in gene expression and cell
behavior, like increased proliferation, survival, motility,
invasiveness, and stimulation of angiogenesis.Our study detected c-Met expression in 90 ESCC pa-
tients and analyzed the relationship between c-Met ex-
pression and clinical features and prognosis. According
to H-score assessment, 43.3% of patients had c-Met
overexpression, similar to other reports in China [11].
The most important finding in this study was that c-Met
overexpression was associated with shorter OS in the pa-
tients with advanced ESCC, which may give clues for
target therapy in advanced ESCC.
One study reported that an increased expression of c-
Met was seen along the metaplasia-adenocarcinoma se-
quence and patients with esophageal adenocarcinoma
with c-Met positive tumors showed lower 6-month
Xu et al. BMC Cancer  (2015) 15:6 Page 6 of 7survival rates after surgical resection than those with c-
Met negative tumors [14]. There were few reports on
ESCC in western countries. Mesteri reported that 7.6%
of ESCC patients had c-Met over-expression, but c-Met
plays no relevant role in ESCC [10]. However, there are
no metastatic patients included in this study and the dif-
ference between stages may cause the different results.
In China, more than 95% esophageal cancer patients are
ESCC. c-Met overexpression of ESCC in China ranges
from 34% to 58%. Our study had similar results. Dong G
finds [15] that metastatic SCC cells that overexpress
c-Met exhibit angiogenesis factor expression and enhance
scattering in response to HGF in vitro, and tumorigenesis
and metastasis in response to HGF in the tumor
microenvironment in vivo. Peng [9] did a meta-analysis
on c-Met expression in gastric carcinoma and found
that higher c-Met gene amplification and expression in
gastric cancer was an indicator of poor prognosis. Up
to now, there is no other study focused on the rela-
tionship between c-Met expression and prognosis in
ESCC in China. Further research still needs.
In our study, patients with c-Met lowexpression had a
better OS than those with c-Met overexpression both in
TP plus nimotuzumab group and in TP group. In c-Met
overexpression group, patients treated with TP plus
nimotuzumab had a worse OS than those treated with
TP alone. On the contrary, in c-Met lowexpression
group, patients treated with TP plus nimotuzumab had a
better OS than those treated with TP alone. This sug-
gests that patients with c-Met overexpression may not
be suitable for anti-EGFR treatment. There has been no
study on anti-EGFR treatment and c-Met expression be-
fore. However, a study finds out that in lung cancer,
amplification of c-Met causes gefitinib resistance by
driving ERBB3-dependent activation of PI3K, a pathway
thought to be specific to EGFR/ERBB family receptors
[16]. Recently, another study in colorectal cancer high-
lights the role of c-Met in mediating primary and
secondary resistance to anti-EGFR therapies and encour-
ages the use of c-Met inhibitors in patients displaying
resistance as a result of c-Met amplification [17]. In the
breast cancer, c-Met contributes to trastuzumab re-
sistance, as inhibition of c-Met sensitizes cells to
trastuzumab-mediated growth inhibition [18]. High gene
copy numbers of c-Met and HGF associate with an in-
creased risk of trastuzumab-based therapy failure in
HER2-positive metastatic breast cancer [19]. In gastric
cancer, HGF activation of c-Met receptors rescues cells
from lapatinib-induced growth inhibition by restimulat-
ing the downstream pathways and restoring normal cell-
cycle progression. This rescue effect could be abrogated
by inhibiting c-Met with PHA-665752 (a highly specific
c-Met inhibitor) or down-regulating c-Met expression
with siRNA [20]. These mechanisms above may exist inESCC which cause anti-EGFR drugs resistance. Further
confirmation is needed.
There were some limitations in this study. First, this
study was conducted in a relatively small sample size.
Secondly, due to a retrospective study, only cancer tis-
sues before treatment were detected. It would be better
that cancer tissues after treatment, lymph nodes, distant
metastasis, and normal tissues adjacent to cancer could
be detected for c-Met IHC and c-Met gene amplifica-
tion. On the other hand, information of patients treated
with different therapies was not well matched. Thus, our
findings should be validated in subsequent prospective
studies in future before clinical application.
In short, c-Met plays an important role in develop-
ment of ESCC and may have an effect on anti-EGFR
therapy, which needs further studies.
Conclusion
Patients with c-Met over-expression had a poorer prog-
nosis than those with c-Met low-expression, suggesting
that c-Met may be an independent prognostic biomarker
in ESCC. Patients with c-Met over-expression treated
with nimotuzumab had a shorter OS, indicating c-Met
might be a predictor of efficacy of anti-EGFR therapy.
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